Collagen Solutions PLC (LON:COS) chief executive Jamal Rushdy said the regenerative medicines specialists was seeing “continued growth as expected”, supported by June’s £5.96mln fundraiser.

“We are also progressing with infrastructure projects to increase our capacity for contract manufacturing while we also expand our tissue supply,” Rushdy added ahead of the company’s annual meeting later in Glasgow.

He said firm is “engaged in active dialogue” with regulators to address questions around cartilage repair product ChondroMimetic, which it hopes will pave the way to a CE Mark.

At the same time, the company’s R&D team is “executing on several key customer product development projects supporting a strong pipeline of contract manufacturing over the next several years”, the Collagen Solutions CEO said.